|Table of Contents|

Expression and clinical significance of HMGB1 and PD-L1 in non-special invasive breast carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
477-481
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of HMGB1 and PD-L1 in non-special invasive breast carcinoma
Author(s):
HUA Xiangqian1; ZHANG Yang2
1.Pathology Department,The Maternal and Child Health Care Hospital of Xiangtan City,Hunan Xiangtan 411100,China;2.Pathology Department,Xiangtan Central Hospital,Hunan Xiangtan 411100,China.
Keywords:
non-special invasive breast carcinoma; high mobility group box 1; programmed cell death ligand 1; clinicopathological features; prognosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.03.015
Abstract:
Objective:To investigate the expression of high mobility group box 1(HMGB1) and programmed cell death ligand 1(PD-L1) in non-special invasive breast carcinoma and their relationship with prognosis.Methods:We collected the pathological and clinical data of 257 cases of non-special invasive type of female invasive breast carcinoma.The expression of HMGB1 and PD-L1 in non-special breast carcinoma and normal breast tissue of the same patient was detected by immunohistochemistry.The relationship between HMGB1 and PD-L1 and clinicopathological parameters was analyzed,and the prognostic value was evaluated.Results:HMGB1 high expression was related to tumor size,histological grade,axillary lymph node metastasis,TNM stage and estrogens receptor(P＜0.05).PD-L1 positive was related to histological grade,axillary lymph node metastasis,TNM stage,estrogen receptor,progesterone receptor,HER2 and molecular types(P＜0.05).In terms of prognosis,HMGB1 high expression and PD-L1 positive significantly affected the five-year recurrence-free survival in patients with non-special invasive breast carcinoma(P＜0.05).Conclusion:HMGB1 high expression and PD-L1 positive are closely related to many poor prognostic factors in non-special invasive breast carcinoma.HMGB1 high expression and PD-L1 positive may be useful in predicting the recurrence of non-special invasive breast carcinoma.

References:

[1]张雪,董晓平,管雅喆,等.女性乳腺癌流行病学趋势及危险因素研究进展［J］.肿瘤防治研究,2021,48(1):87-92. ZHANG X,DONG XP,GUAN YZ,et al.Research progress on epidemiological trend and risk factors of female breast cancer ［J］.Cancer Research on Prevention and Treatment,2021,48(1):87-92.
[2]LUCAS J,HSIEH TC,HALICKA HD,et al.Upregulation of PD L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300 mediated NF κB signaling ［J］.International Journal of Oncology,2018,53(4):1469-1480.
[3]JIN S,YANG Z,HAO X,et al.Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment ［J］.Biomarker Research,2020,8(1):1-8.
[4]MANDKE P,VASQUEZ KM.Interactions of high mobility group box protein 1(HMGB1) with nucleic acids:Implications in DNA repair and immune responses［J］.DNA Repair,2019,83:102701.
[5]陈伦虎,宋方敏,李和平,等.高迁移率族蛋白B1在溃疡性结肠炎组织中的表达及其与氧化应激、屏障功能损伤的相关性研究［J］.现代消化及介入诊疗,2019,24(10):1104-1108. CHEN LH,SONG FM,LI HP,et al.Expression of high mobility group B1 in ulcerative colitis and its correlation with oxidative stress and barrier function damage ［J］.Modern Digestion ＆ Intervention,2019,24(10):1104-1108.
[6]AMORNSUPAK K,THONGCHOT S,THINYAKUL C,et al.HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells ［J］.BMC cancer,2022,22(1):1-13,578-591.
[7]LI P,XU M,CAI H,et al.The effect of HMGB1 on the clinicopathological and prognostic features of cervical cancer［J］.Bioscience Reports,2019,39(5):BSR20181016.
[8]朱健龙,刘涛,邹丹丹,等.肿瘤细胞及间质肿瘤浸润淋巴细胞PD-L1表达与三阴性乳腺癌临床病理特征及预后的关系［J］.中国现代普通外科进展,2020,23(6):474-476. ZHU JL,LIU T,ZOU DD,et al.The relationship between the expression of PD-L1 in tumor cells and stromal tumor infiltrating lymphocyte and the clinicopathological features and prognosis of triple negative breast cancer ［J］.Chin J Curr Adv Gen Surg,2020,23(6):474-476.
[9]HUANG X,DING Q,GUO H,et al.Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma［J］.Hum Pathol,2021,108:42-50.
[10]张雅聪,吕章艳,宋方方,等.全球及我国乳腺癌发病和死亡变化趋势［J］.肿瘤综合治疗电子杂志,2021,7(2):14-20. ZHANG YC,LV ZY,SONG FF,et al.Trends of incidence and mortality of breast cancer worldwide and in China ［J］.Electronic Journal of Cmprehensive Treatment of Cancer,2021,7(2):14-20.
[11]WANG S,ZHANG Y.HMGB1 in inflammation and cancer ［J］.Journal of Hematology & Oncology,2020,13(1):1-4.
[12]WU L,YANG L.The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications ［J］.Oncology Letters,2018,15(5):6799-6805.
[13]CHENG KJ,ALSHAWSH MA,MEJIA MOHAMED EH,et al.HMGB1:an overview of its versatile roles in the pathogenesis of colorectal cancer［J］.Cellular Oncology,2020,43(2):177-193.
[14]NI YA,CHEN H,NIE H,et al.HMGB1:An overview of its roles in the pathogenesis of liver disease［J］.Journal of Leukocyte Biology,2021,110(5):987-998.
[15]CHAI W,YE F,ZENG L,et al.HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells［J］.Journal of Experimental & Clinical Cancer Research,2019,38(1):1-15.
[16]JIA Z,JIANG L,WANG H,et al.MiR-218 restrains proliferation of cervical cancer cells via targeted regulation of HMGB1/RAGE pathway［J］.J BUON,2020,25:2683-2689.
[17]ZHAO Z,HU Z,ZENG R,et al.HMGB1 in kidney diseases［J］.Life Sciences,2020,259:118203.
[18]贾茹,孙媛媛,富伟能.高迁移率族蛋白B-1通过细丝蛋白A影响喉癌细胞迁移［J］.中国医科大学学报,2020,49(6):490-494. JIA R,SUN YY,FU WN.Role of high mobility group box-1 in laryngeal cancer cell migration via filamin A ［J］.Journal of China Medical University,2020,49(6):490-494.
[19]杨随兴，罗毅.HMGB1蛋白在口腔鳞癌组织中的表达及其与患者预后的关系［J］.现代肿瘤医学，2021,29（10）：1691-1696. YANG SX,LUO Y.The relationship between the expression of HMGB1 protein and prognosis in oral squamous cell carcinoma［J］.Modern Oncology，2021,29（10）：1691-1696.
[20]LUAN X,MA C,WANG P,et al.HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition［J］.OncoTargets and Therapy,2017,10:1389-1402.
[21]TRIPATHI A,SHRINET K,KUMAR A.HMGB1 protein as a novel target for cancer ［J］.Toxicology Reports,2019,6:253-261.
[22]HAN Y,LIU D,LI L.PD-1/PD-L1 pathway:current researches in cancer［J］.American Journal of Cancer Research,2020,10(3):727-742.
[23]VRANIC S,CYPRIAN FS,GATALICA Z,et al.PD-L1 status in breast cancer:Current view and perspectives［J］.Semin Cancer Biol,2021:72:146-154.
[24]DI SPAZIO L,RIVANO M,CANCANELLI L,et al.The degree of programmed death-ligand 1(PD-L1) positivity as a determinant of outcomes in metastatic triple-negative breast cancer treated with first-line immune checkpoint inhibitors［J］.Cureus,2022,14(1):e21065.
[25]RIZZO A,RICCI AD.PD-L1,TMB,and other potential predictors of response to immunotherapy for hepatocellular carcinoma:how can they assist drug clinical trials［J］.Expert Opin Investig Drugs,2022,31(4):415-423.
[26]朱蓓,方亮,王营营.非小细胞肺癌患者血清HMGB1和PD-L1检测的临床分析［J］.临床输血与检验,2020,22(1):55-57. ZHU P,FANG L,WANG YY.Significance of serum HMGB1 and PD-L1 detections in patients with non-small cell lung cancer ［J］.J Clin Transfus Lab Med,2020,22(1):55-57.
[27]WANG W,CHAPMAN NM,ZHANG B,et al.Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-κB contributes to UV radiation-induced immune suppression［J］.Cancer Research,2019,79(11):2909-2922.

Memo

Memo:
-
Last Update: 2023-12-29